Volume Alert - GRPN 7.43 Groupon Inc $GRPN Hit a high today

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - GRPN 7.43 Groupon Inc $GRPN Hit a high today of 7.67 Closing the day 11/10/14 at 7.43 -0.07 -0.93% With a day low of 7.42 and a total volume of 12,023,722.

GRPN Recent Posts: http://investorshangout.com/Groupon-Inc-GRPN-54276/

GRPN Groupon Inc Recent Headline News

Final Glance: Internet companies
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — Shares of some top internet companies were mixed at the close of trading:
ZNGA: 2.48 (+0.05), GRPN: 7.43 (-0.07)

Midday Glance: Internet companies
AP - Mon Nov 10, 12:28PM CST
NEW YORK (AP) — Shares of some top internet companies are mixed at 1 p.m.:
ZNGA: 2.48 (+0.05), GRPN: 7.43 (-0.07)

Early Glance: Internet companies
AP - Mon Nov 10, 9:28AM CST
NEW YORK (AP) — Shares of some top internet companies are mixed at 10 a.m.:
ZNGA: 2.48 (+0.05), GRPN: 7.43 (-0.07)

Groupon Unveils a Free Getaways Travel Discovery App for iPhones and Android Devices
Business Wire - Mon Nov 10, 8:02AM CST
Today, Groupon (groupon.com) announced the launch of a new Groupon Getaways travel discovery app (www.groupon.com/getaways/mobile) with enhanced search capabilities, expanding the number of ways that people can use Getaways to help save money when they travel. The new app provides travelers with fast and easy access to more than 25,000 travel deals in destinations around the world.
GRPN: 7.43 (-0.07)

5 Things Groupon, Inc.'s Management Wants You to Know
Sam Mattera, The Motley Fool - Motley Fool - Fri Nov 07, 2:02PM CST
Shares of Groupon surged last Friday following an earnings report that saw the daily deals giant exceed analysts' expectations. Although Groupon shares are still down more than 37% this year, shares are up more than 20% since late last week. ...
GRPN: 7.43 (-0.07), AAPL: 108.83 (-0.18)

Groupon Earnings Are A Mixed Bag
The Panoramic View - at Seeking Alpha - Thu Nov 06, 2:36AM CST

GRPN: 7.43 (-0.07)

What I Liked Most About Groupon's Quarter (That No One's Talking About)
Brian Nichols, The Motley Fool - Motley Fool - Wed Nov 05, 2:33PM CST
After falling nearly 50% in 2014, Groupon 's stock last Friday soared higher by 22% after the company reported earnings. Many investors are now open to the idea of giving Groupon's stock another shot but, ironically, this change in sentiment seems...
GRPN: 7.43 (-0.07)

2 Great Consumer Stocks Under $10 This Holiday Season - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Wed Nov 05, 9:46AM CST
These consumer stocks could be interesting choices for investors this holiday season.
GRPN: 7.43 (-0.07), OWW: 7.55 (-0.13)

Groupon Kicks Off the Holidays with Giveaways, a New Gift Shop and the Hottest Toys
Business Wire - Wed Nov 05, 9:18AM CST
Groupon (NASDAQ: GRPN) (http://www.groupon.com) today announced that it's kicking off this holiday season with a new Gift Shop, Holiday Head Start Giveaway and Top 20 Toy List. The Holiday Head Start Giveaway encourages customers to check Groupon today and tomorrow to see if they're one of the five people to score a $10,000 holiday shopping spree. Every customer will score between 5 and 100 percent off any one deal. Customers needing some inspiration are encouraged to shop the all new 2014 Holiday Gift Shop. To round out its one-stop holiday destination, Groupon has also assembled a collection of some of the hottest toys, including:
GRPN: 7.43 (-0.07)

Quarterly Earnings Releases, New Data Centre, Technical Updates, and Product Launch - Research Reports on Groupon, Salesforce, TSMC, Seagate and ADI
PR Newswire - Wed Nov 05, 7:35AM CST
Today, Analysts Review released its research reports regarding Groupon, Inc. (NASDAQ: GRPN), Salesforce.com, Inc. (NYSE: CRM), Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM), Seagate Technology PLC (NASDAQ: STX) and Analog Devices, Inc. (NASDAQ: ADI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7701-100free.
STX: 61.77 (+0.21), ADI: 50.42 (+0.18), TSM: 22.26 (+0.44), GRPN: 7.43 (-0.07), CRM: 64.45 (+0.48)

Most active Nasdaq-traded stocks
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SAPE: 24.65 (-0.02), FB: 75.00 (-0.60), PLUG: 5.28 (-0.02), GERN: 2.30 (-0.03), ODP: 6.49 (-0.01), ARCP: 8.50 (-0.29), INTC: 33.26 (-0.32), GRPN: 7.43 (-0.07), MSFT: 48.89 (+0.21), AAPL: 108.83 (-0.18), CSCO: 25.15 (-0.18)

Groupon continues post-earnings rally/short-squeeze
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 2:40PM CST

GRPN: 7.43 (-0.07)

Groupon Inc. (GRPN) Stock Research Links

GRPN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading